Is the era of the big phar­ma megamerg­er about to re­turn?

This week­end, the news broke that As­traZeneca and Bris­tol My­ers Squibb were al­leged­ly in...

For years, No­vo Nordisk and Eli Lil­ly have dom­i­nat­ed the con­ver­sa­tion sur­round­ing obe­si­ty med­i­cines as the du­op­oly com­petes to lead the largest phar­ma­ceu­ti­cal cat­e­go­ry in...

Pfiz­er an­nounced $2.5 bil­lion in cost cuts, tak­ing an­oth­er step in a post-Covid strat­e­gy that has been de­fined by mid-sized deal­mak­ing and con­stant ex­pense trim­ming...